ClinicalTrials.gg
RecruitingNCT06580392Updated Jul 11, 2025

CCM and Implementation of Guideline-Directed Medical Therapy in Patients With Heart Failure (Fix-GDMT-HF)

An observational study in Heart Failure, sponsored by Impulse Dynamics. Recruiting at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Impulse Dynamics · Observational

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Heart Failure by Impulse Dynamics — 4 open to participants now, 6 under way, none of them phase 3. Heart Failure · Impulse Dynamics.

Started
2025
with 2 others
Observational
4 of 11
3 open now
Registered
9th of 11
by date

Among the 11 studies in Heart Failure by Impulse Dynamics, this one is one of 3 that started in 2025, is one of 4 observational ones, and was the 9th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

4 of the 11 studies in Heart Failure by Impulse Dynamics are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Heart Failure by Impulse Dynamics, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the impact of Cardiac Contractility Modulation (CCM) therapy on the initiation and up-titration of Guideline-Directed Medical Therapy (GDMT) in patients with heart failure (HF). This will be assessed by the change in Quad Medication Score (QMS) from baseline (pre-CCM) to 6-month following post-CCM device implant.

Read the detailed description

Design Prospective, non-randomized, comparison analysis of medication use and dosing at pre/post CCM therapy. The Fix-GDMT-HF study aims to enroll up to 200 subjects (100 in Investigational Arm and up to 100 in Registry Arm). Subjects identified not eligible to participate in the investigational arm can participate in the registry arm.

Method

  • Subjects with QMS ≤ 5, eGFR ≥15, diagnosed symptomatic heart failure and LVEF ≤40% will be enrolled after review and approval by a member of the steering committee. Eligible subjects will receive CCM therapy and be enrolled in the investigational arm of the study. Medication optimization(Med op#2) will be assessed after implantation(approx. 3month post implant), followed by evaluation of QMS and other endpoints at 6 and 12 months. A target of 100 patients will be enrolled in the investigational arm.
  • After medical optimization (Med op# 1), if the patient has QMS > 5 or identified during SC review as not eligible to participate in investigational arm can participate in the registry arm. They will continue treatment guided by local practice (including potential CCM implant) with QMS assessment (and other data collection as patients in investigational arm) at 6- and 12-month visit. The registry arm will be restricted to 100 patients.

Endpoints

Primary Endpoint:

  • Change in the Quad Medication Score (QMS) from baseline (pre-CCM) to 6-month follow-up (post-CCM) of the Optimizer device implant.

Secondary Endpoints:

  • Change in loop diuretic dose from baseline to 6-month follow-up.
  • Change in eGFR from baseline to 6-month follow-up.
  • Change in SBP from baseline to 6-month follow-up.
  • Adverse events (AEs) associated with CCM therapy.
  • Change in HR among patients with concomitant cardiac rhythm management (CRM) devices.
  • Percentage of patients achieving maximal/optimal GDMT following CCM therapy.
  • GDMT adherence as measured by change in QMS score from 6 months (post-CCM) to 12 months (post-CCM).

Patients

Investigational arm - 100 subjects complete the study with 12- month of follow-up.

Registry arm - restricted to 100 subjects

Sites 10 sites in Germany \& Italy. 10 sites in the USA.

Duration

The entire study is expected to take approximately 24 months or (until the target number of subjects has been reached), including the enrolment and follow-up periods.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Change in Quad medication score
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Subject selection will be based on specific inclusion and exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults (≥18 years) diagnosed with symptomatic heart failure
  2. Patients with Heart failure with reduced (HFrEF) where the Ejection Fraction (EF) is ≤40%

    - Historical LVEF assessed up to 6 months prior to consent by any modality can be used if available

  3. Patients can have an active concomitant CRT device already - implanted provided the following criteria:

    • CRT device has been implanted >1 year
    • Patients are functional class III-IV

Exclusion criteria

Exclusion Criteria:

  1. Patients that are unlikely to adhere to medical therapy for reasons other than intolerance or .
  2. Patients with a QMS score >5
  3. \<15
  4. Patients with a concomitant CRT device that has already been implanted and deemed to be a responder
  5. Patients with class I indication for a concomitant CRT device
  6. Patients with significant comorbidities or conditions that may interfere with the study assessments
  7. Patients with contraindications to CCM therapy or unable to undergo implantation
  8. Severe stenotic valve disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Change in Quad Medication Score

    Change in the Quad Medication Score (QMS) from baseline (pre-CCM) to 6-month follow-up (post-CCM) of the Optimizer device implant

    Time frame: 6 month

Secondary outcomes

  1. Change in loop diuretic dose

    Change in loop diuretic dose from baseline to 6-month follow-up.

    Time frame: 6-month

  2. Change in eGFR

    Change in eGFR from baseline to 6-month follow-up

    Time frame: 6-month

  3. Change in SBP

    Change in SBP from baseline to 6-month follow-up.

    Time frame: 6-month

  4. Adverse events (AEs) associated with CCM therapy.

    Adverse events (AEs) associated with CCM therapy.

    Time frame: 12-month

  5. Percentage of patients achieving maximal/optimal GDMT following CCM therapy

    Percentage of patients achieving maximal/optimal GDMT following CCM therapy

    Time frame: 12-month

  6. GDMT adherence as measured by change in QMS score

    GDMT adherence as measured by change in QMS score from 6 months (post-CCM) to 12 months (post-CCM).

    Time frame: 12-month

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jun 2027, 28 months after the start.

Of 183 industry-sponsored observational studies under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 57. This study's planned 28 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2024
First posted
Aug 30, 2024
StartActual
Feb 1, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2027
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06580392
Lead sponsor
Impulse Dynamics
Responsible party
Sponsor
First posted
Aug 30, 2024
Start date
Feb 1, 2025
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 11, 2025

Study contacts

Gary Cranke
Contact
gcranke@impulsedynamics.com
(856) 642-9933
Rachael Riccitello
Contact
rriccitello@impulsedynamics.com
(856) 642-9933

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion